Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

(2017) Joseph E. Tota et al.   JNCI-Journal of the National Cancer Institute

HPV vaccine coverage is increasing in Australia

(2017) Julia ML Brotherton et al.   MEDICAL JOURNAL OF AUSTRALIA

Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction

(2017) Lili Ding et al.   VACCINE

Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study

(2017) Lamb F et al.   BMJ Open

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

(2017) Karen Canfell et al.   PLOS MEDICINE

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

(2017) Joseph E. Tota et al.   JNCI-Journal of the National Cancer Institute

Comparison of the Roche Cobas® 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus

(2016) S. Phillips et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

(2016) Rengaswamy Sankaranarayanan et al.   LANCET ONCOLOGY

HPV vaccine impact in Australian women: ready for an HPV-based screening program

(2016) Julia ML Brotherton et al.   MEDICAL JOURNAL OF AUSTRALIA

Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study

(2015) Eric P F Chow et al.   LANCET INFECTIOUS DISEASES

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

(2015) Elmar A. Joura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program

(2015) Sarah L. Osborne et al.   VACCINE

Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens

(2014) J. E. Tota et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program

(2014) Sepehr N. Tabrizi et al.   JOURNAL OF CLINICAL VIROLOGY

Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data

(2014) Megan A. Smith et al.   JOURNAL OF INFECTIOUS DISEASES

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

(2014) Sepehr N Tabrizi et al.   LANCET INFECTIOUS DISEASES

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

(2014) E. Crowe et al.   BMJ-British Medical Journal

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

(2013) Dorota M Gertig et al.   BMC Medicine

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

(2013) Silvia de Sanjosé et al.   EUROPEAN JOURNAL OF CANCER

Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach

(2013) Julia M L Brotherton et al.   MEDICAL JOURNAL OF AUSTRALIA

Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey

(2013) Julia M.L. Brotherton et al.   VACCINE

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

(2013) H. Ali et al.   BMJ-British Medical Journal

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

(2012) S. N. Tabrizi et al.   JOURNAL OF INFECTIOUS DISEASES

Global Burden of Human Papillomavirus and Related Diseases

(2012) David Forman et al.   VACCINE

Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis

(2011) Beibei Lu et al.   BMC INFECTIOUS DISEASES

Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program

(2011) Suzanne M Garland et al.   BMC Medicine

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples

(2011) Samuel Bernal Martínez et al.   JOURNAL OF VIROLOGICAL METHODS

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

(2011) Dorota M. Gertig et al.   Sexual Health

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

(2010) Basil Donovan et al.   LANCET INFECTIOUS DISEASES

Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97

(2008) Z. Chen et al.   JOURNAL OF VIROLOGY

Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler® 480 system

(2007) Matthew P. Stevens et al.   JOURNAL OF VIROLOGICAL METHODS